99 related articles for article (PubMed ID: 10505039)
1. Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA.
Dørum A; Hovig E; Tropé C; Inganas M; Møller P
Eur J Cancer; 1999 May; 35(5):779-81. PubMed ID: 10505039
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations.
Borg A; Dørum A; Heimdal K; Maehle L; Hovig E; Møller P
Dis Markers; 1999 Oct; 15(1-3):79-84. PubMed ID: 10595257
[TBL] [Abstract][Full Text] [Related]
3. The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer.
Heimdal K; Maehle L; Apold J; Pedersen JC; Møller P
Eur J Cancer; 2003 Oct; 39(15):2205-13. PubMed ID: 14522380
[TBL] [Abstract][Full Text] [Related]
4. Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer.
Dørum A; Heimdal K; Hovig E; Inganäs M; Møller P
Am J Hum Genet; 1999 Sep; 65(3):671-9. PubMed ID: 10441573
[TBL] [Abstract][Full Text] [Related]
5. Genetic epidemiology of BRCA1 mutations in Norway.
Møller P; Heimdal K; Apold J; Fredriksen A; Borg A; Hovig E; Hagen A; Hagen B; Pedersen JC; Maehle L; ;
Eur J Cancer; 2001 Dec; 37(18):2428-34. PubMed ID: 11720839
[TBL] [Abstract][Full Text] [Related]
6. TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival.
Kringen P; Wang Y; Dumeaux V; Nesland JM; Kristensen G; Borresen-Dale AL; Dorum A
BMC Cancer; 2005 Oct; 5():134. PubMed ID: 16229746
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study.
Bjørge T; Lie AK; Hovig E; Gislefoss RE; Hansen S; Jellum E; Langseth H; Nustad K; Tropé CG; Dørum A
Br J Cancer; 2004 Nov; 91(10):1829-34. PubMed ID: 15477862
[TBL] [Abstract][Full Text] [Related]
8. Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families.
Verhoog LC; van den Ouweland AM; Berns E; van Veghel-Plandsoen MM; van Staveren IL; Wagner A; Bartels CC; Tilanus-Linthorst MM; Devilee P; Seynaeve C; Halley DJ; Niermeijer MF; Klijn JG; Meijers-Heijboer H
Eur J Cancer; 2001 Nov; 37(16):2082-90. PubMed ID: 11597388
[TBL] [Abstract][Full Text] [Related]
9. The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series.
Møller P; Borg A; Heimdal K; Apold J; Vallon-Christersson J; Hovig E; Maehle L; ;
Eur J Cancer; 2001 May; 37(8):1027-32. PubMed ID: 11334729
[TBL] [Abstract][Full Text] [Related]
10. The frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populations.
Rudkin TM; Hamel N; Galvez M; Hogervorst F; Gille JJ; Møller P; Apold J; Foulkes WD
BMC Med Genet; 2006 Mar; 7():15. PubMed ID: 16509964
[TBL] [Abstract][Full Text] [Related]
11. A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing.
Dørum A; Møller P; Kamsteeg EJ; Scheffer H; Burton M; Heimdal KR; Maehle LO; Hovig E; Tropé CG; van der Hout AH; van der Meulen MA; Buys CH; te Meerman GJ
Eur J Cancer; 1997 Dec; 33(14):2390-2. PubMed ID: 9616287
[TBL] [Abstract][Full Text] [Related]
12. High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.
Bogdanova NV; Antonenkova NN; Rogov YI; Karstens JH; Hillemanns P; Dörk T
Clin Genet; 2010 Oct; 78(4):364-72. PubMed ID: 20569256
[TBL] [Abstract][Full Text] [Related]
13. [The prevalence of BRCA1 mutations among families at high-risk of breast and ovarian cancer in province of Malopolska between 2004-2009].
Blecharz P; Szatkowski W; Klimek M; Urbański K
Przegl Lek; 2009; 66(12):1046-8. PubMed ID: 20514903
[TBL] [Abstract][Full Text] [Related]
14. Genotype-phenotype correlations among BRCA1 4153delA and 5382insC mutation carriers from Latvia.
Plakhins G; Irmejs A; Gardovskis A; Subatniece S; Rozite S; Bitina M; Keire G; Purkalne G; Teibe U; Trofimovics G; Miklasevics E; Gardovskis J
BMC Med Genet; 2011 Oct; 12():147. PubMed ID: 22032251
[TBL] [Abstract][Full Text] [Related]
15. The contribution of founder mutations in BRCA1 to breast cancer in Belarus.
Uglanitsa N; Oszurek O; Uglanitsa K; Savonievich E; Lubiński J; Cybulski C; Debniak T; Narod SA; Gronwald J
Clin Genet; 2010 Oct; 78(4):377-80. PubMed ID: 20507347
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of BRCA1 founder mutations in western Poland.
Jasinska A; Krzyzosiak WJ
Hum Mutat; 2001; 17(1):75. PubMed ID: 11139251
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer.
Anton-Culver H; Cohen PF; Gildea ME; Ziogas A
Eur J Cancer; 2000 Jun; 36(10):1200-8. PubMed ID: 10882857
[TBL] [Abstract][Full Text] [Related]
18. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
[TBL] [Abstract][Full Text] [Related]
19. First BRCA1 and BRCA2 gene testing implemented in the health care system of Stockholm.
Arver B; Borg A; Lindblom A
Genet Test; 2001; 5(1):1-8. PubMed ID: 11336395
[TBL] [Abstract][Full Text] [Related]
20. Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes.
Chang-Claude J; Dong J; Schmidt S; Shayeghi M; Komitowski D; Becher H; Stratton MR; Royer-Pokora B
J Med Genet; 1998 Feb; 35(2):116-21. PubMed ID: 9507390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
